Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1455257
Reference Type
Journal Article
Title
In vitro Evaluation of Terminalia arjuna on Calcium Phosphate and Calcium Oxalate Crystallization
Author(s)
Chaudhary, A; Singla, SK; Tandon, C
Year
2010
Is Peer Reviewed?
Yes
Journal
Indian Journal of Pharmaceutical Sciences
ISSN:
0250-474X
EISSN:
1998-3743
Volume
72
Issue
3
Page Numbers
340-345
Language
English
PMID
21188043
DOI
10.4103/0250-474X.70480
Abstract
Urinary stones are one of the oldest and the most common afflictions in humans. This disease has tormented humans since the earliest records of civilization. Ten percent of men and 3 % of women have a stone during their adult lives. Calcium containing stones are the most common comprising about 75 % of all urinary calculi, which may be in the form of pure calcium oxalate (50 %) or calcium phosphate (5 %) or a mixture of both (45 %). A number of plants have been mentioned in the Indian ayurvedic system, which plays a vital role in the inhibition of kidney stones. In the present study, the inhibitory potency of crude extracts or fractions of successive solvent extractions of Terminalia arjuna bark was evaluated on various stages of formation of calcium phosphate and on the growth of calcium oxalate monohydrate crystals in vitro. Results obtained indicated that Terminalia arjuna bark has the potential to inhibit the formation of both calcium phosphate and calcium oxalate crystals in vitro. Butanol fraction of Terminalia arjuna extract was the most effective in inhibiting formation of calcium phosphate and calcium oxalate crystals in vitro.
Tags
IRIS
•
n-Butanol
Database searches
Pubmed
Source – January 2013 (private)
Pubmed - 1/2013
Merged reference set - 1/2013
Excluded (not pertinent)
Use in sample prep or assay
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity